AbbVie Inc.ABBVNYSE
Loading
SG&A Expense Growth TrendStable
Percentile Rank74
3Y CAGR+38.7%
5Y CAGR-7.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+38.7%/yr
vs +146.9%/yr prior
5Y CAGR
-7.6%/yr
Recent acceleration
Acceleration
-108.1pp
Decelerating
Percentile
P74
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive declineStable
| Period | Value |
|---|---|
| Q4 2025 | 9.13% |
| Q3 2025 | 9.71% |
| Q2 2025 | -1.21% |
| Q1 2025 | -14.58% |
| Q4 2024 | -8.32% |
| Q3 2024 | 24.52% |
| Q2 2024 | 1.87% |
| Q1 2024 | 3.82% |
| Q4 2023 | -5.31% |
| Q3 2023 | 3.18% |
| Q2 2023 | 7.54% |
| Q1 2023 | -11.06% |
| Q4 2022 | 3.42% |
| Q3 2022 | -38.95% |
| Q2 2022 | 73.07% |
| Q1 2022 | -4.08% |
| Q4 2021 | 5.74% |
| Q3 2021 | -2.56% |
| Q2 2021 | 11.33% |
| Q1 2021 | -12.04% |
| Q4 2020 | 13.53% |
| Q3 2020 | -19.31% |
| Q2 2020 | 108.08% |
| Q1 2020 | -13.12% |
| Q4 2019 | 17.74% |
| Q3 2019 | 0.18% |
| Q2 2019 | -1.55% |
| Q1 2019 | -12.91% |
| Q4 2018 | 0.52% |
| Q3 2018 | 9.03% |
| Q2 2018 | -1.73% |
| Q1 2018 | -8.20% |
| Q4 2017 | 33.91% |
| Q3 2017 | -3.45% |
| Q2 2017 | 9.91% |
| Q1 2017 | -16.94% |
| Q4 2016 | 19.70% |
| Q3 2016 | -5.80% |
| Q2 2016 | 8.19% |
| Q1 2016 | -21.99% |